Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors (MK-1200-002)

Trial Identifier: 1200-002
Sponsor: MSD
Start Date: February 2024
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English

Trial Locations

Country Location
Australia, Victoria Melbourne, Victoria, Australia, 3004
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 8420383
China, Beijing Beijing, China, 100142
China, Fujian Fuzhou, Fujian, China, 350014
China, Jiangsu Huai'an, Jiangsu, China, 223300
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Israel, N/A Tel Aviv, N/A, Israel, 6423906
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
United States, KY Louisville, KY, United States, 40245
United States, MI Grand Rapids, MI, United States, 49546
United States, TX San Antonio, TX, United States, 78229
United States, UT West Valley City, UT, United States, 84119
United States, VA Charlottesville, VA, United States, 22908